S'abonner

The pharmacokinetics of transdermal fentanyl delivered with and without controlled heat - 29/08/11

Doi : 10.1016/S1526-5900(03)00618-7 
Michael A Ashburn * , L.Lazarre Ogden , Jie Zhang , Georgette Love , Susan V Basta §
* Department of Pharmacy Practice, University of Utah Health Sciences Center, Salt Lake City, Utah, USA 
dagger; Department of Anesthesiology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA 
 Acute Pain Service, Department of Anesthesiology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA 
§ Palliative Care Service, Department of Anesthesiology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA 

*Address reprint requests to Michael A. Ashburn, MD, MPH, ZARS, Inc, Suite 320 350 West, 800 North, Salt Lake City, UT 84103, USA

Abstract

Preliminary reports have demonstrated that the application of local heat to the transdermal fentanyl patch significantly increased systemic delivery of fentanyl. The objective of this study was to further evaluate the pharmacokinetic effect of local heat administration on fentanyl drug delivery through the transdermal fentanyl patch delivery system in volunteers. In addition, the study was intended to document the effect of heat on steady-state transdermal fentanyl delivery. This was an open, 3-period, crossover study that evaluated the pharmacokinetics and safety of 25 μg/h transdermal fentanyl administered with and without local heat. During Sessions A and B, subjects received transdermal fentanyl for a 30-hour period. During Session A, heat was applied for 1 hour at the 24-hour time point during the 30-hour period. During Session B, heat was applied for the first 4 hours and then again for 1 hour at the 24-hour time point during the 30-hour period. The order of Sessions A and B was randomized, and a minimum of 2 weeks separated the sessions. Five of the 10 subjects returned to participate in Session C. During Session C, subjects received transdermal fentanyl 25 μg/h for 18 hours. Heat was applied during the first 4 hours of administration and then again for 15-minute periods at the 12- and 16-hour time points. Arterial blood samples for determination of serum fentanyl concentration were collected. Maximum concentration (Cmax), time to maximum concentration (tmax), and area under the curve (AUC) were determined for each treatment period. Sedation, vital signs, oxygen saturation, and adverse events were recorded. During a period of 36 hours, there were no significant differences in Cmax, AUC, or Tmax between transdermal fentanyl delivery with no heat and heat. However, significant differences were seen during the first 4 hours, with Cmax and AUC values almost 3 times higher for the heated administrations than for the administrations without heat. With heat, the mean Cmax was 0.63 ng/mL compared with a Cmax of 0.24 ng/mL without heat (P = .007). With early heat, the mean AUC was 1.22 ng/mL · h compared with 0.42 ng/mL · h without heat (P = .003). There was no statistically significant difference between the median times to achieve peak values (Tmax) during the first 4 hours. The addition of heat at 24 hours resulted in rapid increases in serum fentanyl concentrations for both groups and higher serum fentanyl concentrations for the administration that did not receive heat previously. Applying heat for 15 minutes at the 12-hour and 16-hour time points produced a rapid but short duration increase in serum fentanyl concentrations. The results suggest controlled heat might be used to significantly shorten the time needed to reach clinically important fentanyl concentrations. Controlled heat might be useful to produce rapid increases in serum concentrations for the rapid treatment of breakthrough pain.

Le texte complet de cet article est disponible en PDF.

Keywords : Transdermal fentanyl, breakthrough pain, opioid analgesic, cancer pain


Plan


 Supported by a grant from ZARS, Inc, Salt Lake City, Utah. Dr Ashburn is currently Vice President for Clinical and Regulatory Affairs at ZARS. He was also a founder of ZARS in 1996 and is an officer of the company.


© 2003  American Pain Society. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 4 - N° 6

P. 291-297 - août 2003 Retour au numéro
Article suivant Article suivant
  • Long-term management of noncancer pain with transdermal therapeutic system-fentanyl
  • Kyriaki Mystakidou, Efi Parpa, Eleni Tsilika, Athina Mavromati, Vassilios Smyrniotis, Stavroula Georgaki, Lambros Vlahos

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.